Prescient Therapeutics Limited (ASX: PTX) has launched a Share Purchase Plan (SPP) targeting to raise $8,000,000 at $0.175/share, representing a discount of approximately 14.6% to Prescient’s 5-day VWAP (calculated on 23rd August 2022).
The funds will be used to progress Prescient’s deep pipeline of innovative cancer therapies, namely the ongoing clinical development of its targeted therapies PTX-100 and PTX-200, and progressing its innovative cell therapies towards and into first-in-human clinical studies. Funds will also go towards general working capital and costs of the offer.
*This offer represents a 14.6% discount to the volume weighted average price (VWAP) over the 5 trading days before the date the SPP was announced. All applications and monies must be received by 5pm (AEDT) 4th October 2022.
Prescient Therapeutics’ next-gen tech is revolutionising the US$280 billion oncology industry, putting the company at the forefront of the fastest-growing area of the biggest market in healthcare. Developed along with leading cancer researchers from UPenn, Oxford and the Peter MacCallum Cancer Centre, Prescient’s superior technologies built around a scalable and highly commercialised business model position the company to be a potential winner in an industry on the threshold of revolutionary and sizeable growth.
Please join Prescient CEO and Managing Director Steven Yatomi-Clarke for a shareholder briefing for an update on details of the Share Purchase Plan, use of funds and how to participate.
In this session, Steven will also discuss:
It will be a fascinating look into why Prescient’s highly scalable business model gives them multiple shots on goal in oncology, the largest sector of the global healthcare market at US$280b.
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach* provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.
This is not an offer of securities in any place outside Australia or New Zealand and does not take into account your individual investment objectives, financial situation or particular needs. An investment in the Company is speculative. Therefore, you should obtain independent financial and taxation advice before making an investment decision. Before making an investment decision, you should read the SPP terms in the Offer Booklet.
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.
